Stock Events

Stock Events

NewcelX 

$2.1
0
+$0.11+5.53% Wednesday 04:00

Statistics

Day High
2.1
Day Low
1.98
52W High
-
52W Low
-
Volume
19
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

25FebExpected
Q1 2024
Q3 2025
Q4 2025
-84
-83.67
-83.33
-83
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NCEL.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Jazz Pharmaceuticals
JAZZ
Mkt Cap11.51B
Jazz Pharmaceuticals competes directly with NLS Pharmaceutics in the narcolepsy treatment market, offering Xyrem and Xywav, leading treatments for cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients.
Takeda Pharmaceutical
TAK
Mkt Cap59.2B
Takeda Pharmaceutical Company offers Wakix (pitolisant), which competes in the narcolepsy treatment market, particularly targeting excessive daytime sleepiness, a key area for NLS Pharmaceutics.
Heron Therapeutics
HRTX
Mkt Cap150.68M
Heron Therapeutics, with its focus on CNS disorders including treatments for postoperative pain, indirectly competes with NLS Pharmaceutics by targeting overlapping areas in the central nervous system disorder treatment market.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap35.03B
Teva Pharmaceutical Industries offers several CNS disorder treatments, including generic versions of modafinil and armodafinil for narcolepsy, directly competing with NLS Pharmaceutics' focus on narcolepsy and sleep disorders.
Biogen
BIIB
Mkt Cap26.03B
Biogen competes in the broader CNS disorder space, including multiple sclerosis and Alzheimer's, which overlaps with NLS Pharmaceutics' focus on central nervous system disorders, albeit in different therapeutic areas.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.78B
ACADIA Pharmaceuticals, with its focus on CNS disorders such as Parkinson’s disease psychosis, competes in the broader market for neurological treatments, indirectly competing with NLS Pharmaceutics.
Alkermes
ALKS
Mkt Cap5.81B
Alkermes competes in the CNS therapeutic area with treatments for schizophrenia, bipolar I disorder, and depression, indirectly competing with NLS Pharmaceutics by targeting the broader CNS disorder market.
Neurocrine Biosciences
NBIX
Mkt Cap13.21B
Neurocrine Biosciences focuses on neurological and endocrine diseases, including treatments for tardive dyskinesia and Parkinson’s disease, placing it in indirect competition with NLS Pharmaceutics in the CNS disorder space.

About

NewcelX Ltd., a biotechnology company, engages in developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company was founded in 2008 and is headquartered in Zurich, Switzerland.
Show more...
CEO
Mr. Ronen Twito CPA
Employees
11
Country
US
ISIN
CH1442297896

Listings

XNAS
US
NCEL
BOATS
BOATS
NCEL.BOATS

0 Comments

Share your thoughts

FAQ

What is NewcelX stock price today?▼
The current price of NCEL.BOATS is $2.1 USD — it has increased by +5.53% in the past 24 hours. Watch NewcelX stock price performance more closely on the chart.
What is NewcelX stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange NewcelX stocks are traded under the ticker NCEL.BOATS.
When is the next NewcelX earnings date?▼
NewcelX is going to release the next earnings report on September 02, 2026.
How many employees does NewcelX have?▼
As of April 08, 2026, the company has 11 employees.
In which sector is NewcelX located?▼
NewcelX operates in the Health Care sector.
When did NewcelX complete a stock split?▼
NewcelX has not had any recent stock splits.
Where is NewcelX headquartered?▼
NewcelX is headquartered in Zurich, US.